Korglutide

Oral GLP-1 Peptide for Safe, Muscle-Preserving Weight Loss
Korglutide is a next-generation oral GLP-1 peptide (7 amino acids) developed by Caregen for weight loss and metabolic health. In clinical studies, it has demonstrated meaningful weight reduction, significant visceral fat decrease, and preservation of lean muscle mass—supporting improved body composition beyond simple weight loss. This enables a more balanced and sustainable approach to metabolic management. With its convenient once-daily oral format and completed FDA New Dietary Ingredient (NDI) notification, Korglutide is well positioned for scalable commercialization in the global nutraceutical market.

• In a randomized, double-blind, placebo-controlled Phase III study involving obese individuals (BMI ≥ 30) and obese individuals with type 2 diabetes (BMI ≥ 27), Korglutide demonstrated significant improvements across key metabolic parameters. Body weight decreased by -10.78% (-9.3 kg), BMI by -10.83%, HbA1c by -0.9%, WHR by -5.2%, and body fat mass by -7.1% (-6.65 kg), while skeletal muscle mass reduction remained limited to -2.9% (-0.27 kg).
• A second Phase III study in non-obese individuals, including those with Normal Weight Obesity (NWO), showed an -8.02% (-5.2 kg) reduction in body weight and an -8.26% reduction in BMI, with body fat decreased by -9.6% and visceral fat level reduced by -9.21%.

These results indicate that Korglutide supports fat reduction while minimizing muscle loss in both obese and non-obese individuals. With completed FDA New Dietary Ingredient (NDI) registration in January 2026, Korglutide is well positioned for global commercialization in the nutraceutical market.